Trial Profile
Nobori umirolimus-eluting stent versus Xience/Promus everolimus-eluting stent in patients in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Umirolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- 30 Mar 2020 Primary endpoint has not been met. (Device-oriented composite endpoints (DOCE))
- 30 Mar 2020 Results (N=2503) comparing Seven Year clinical outcomes between BP-BES (n=1343) and DP-EES (n=1160), presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
- 25 Sep 2018 Results assessing Five-Year Clinical Outcomes of NOBORI Biolimus-Eluting Stent versus XIENCE Everolimus-Eluting Stent in Diabetic Patients (n=1069) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics